108 related articles for article (PubMed ID: 9778672)
1. Raloxifene: a new class of anti-estrogens for the prevention of osteoporosis.
Kupecz D
Nurse Pract; 1998 Sep; 23(9):91-3. PubMed ID: 9778672
[No Abstract] [Full Text] [Related]
2. Raloxifene for postmenopausal osteoporosis.
Med Lett Drugs Ther; 1998 Mar; 40(1022):29-30. PubMed ID: 9529516
[No Abstract] [Full Text] [Related]
3. A new alternative to estrogen: raloxifene.
Runowicz C
Health News; 1998 Jun; 4(8):4. PubMed ID: 9644506
[No Abstract] [Full Text] [Related]
4. Raloxifene: designer estrogen for preventing postmenopausal osteoporosis.
Park L; Evans MF
Can Fam Physician; 1999 May; 45():1191-3. PubMed ID: 10349062
[No Abstract] [Full Text] [Related]
5. [Raloxifene].
Hofbauer LC; Heufelder AE
Dtsch Med Wochenschr; 1999 Jan; 124(1-2):19-20. PubMed ID: 9951454
[No Abstract] [Full Text] [Related]
6. From blunderbuss to magic bullet?
Alderman C
Nurs Stand; 1998 Jan 21-27; 12(18):18. PubMed ID: 9485842
[No Abstract] [Full Text] [Related]
7. New drug approved to help prevent osteoporosis.
Mayo Clin Health Lett; 1998 Mar; 16(3):3. PubMed ID: 9516369
[No Abstract] [Full Text] [Related]
8. Raloxifene: a selective estrogen receptor modulator.
Scott JA; Da Camara CC; Early JE
Am Fam Physician; 1999 Sep; 60(4):1131-9. PubMed ID: 10507743
[TBL] [Abstract][Full Text] [Related]
9. 'Smart' estrogens emerging.
Harv Heart Lett; 1998 Mar; 8(7):4-5. PubMed ID: 9516317
[No Abstract] [Full Text] [Related]
10. Effects of raloxifene in postmenopausal women.
Cole RC; Flaws JA; Bush TL
N Engl J Med; 1998 Apr; 338(18):1313; author reply 1313-4. PubMed ID: 9565492
[No Abstract] [Full Text] [Related]
11. Raloxifene approval ushers in new drug class for osteoporosis. Estrogen-receptor effects vary by tissue type.
Am J Health Syst Pharm; 1998 Jan; 55(2):104. PubMed ID: 9465969
[No Abstract] [Full Text] [Related]
12. [Current trends in prevention and therapy of postmenopausal osteoporosis].
Rossi G
Recenti Prog Med; 1998 Jun; 89(6):288. PubMed ID: 9658894
[No Abstract] [Full Text] [Related]
13. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505
[TBL] [Abstract][Full Text] [Related]
14. [Agonists-antagonists of estrogens, their potential use in prophylaxis and treatment of osteoporosis].
Hoszowski K
Pol Tyg Lek; 1995 Nov; 50(44-47):41-2. PubMed ID: 8643425
[TBL] [Abstract][Full Text] [Related]
15. [Raloxifene: a new molecule for the prevention of menopausal osteoporosis].
Oliaro A
Minerva Ginecol; 1998 Mar; 50(3):XII-XIII. PubMed ID: 9595915
[No Abstract] [Full Text] [Related]
16. Medications for postmenopausal osteoporosis prevention.
Harv Womens Health Watch; 2002 Dec; 10(4):6-7. PubMed ID: 12499127
[No Abstract] [Full Text] [Related]
17. Clinical efficacy of SERMs.
Dere WH
Aging (Milano); 1998 Apr; 10(2):160-1. PubMed ID: 9666217
[No Abstract] [Full Text] [Related]
18. Tamoxifen for prevention of breast cancer.
Med Lett Drugs Ther; 1999 Jan; 41(1043):1-2. PubMed ID: 9924486
[No Abstract] [Full Text] [Related]
19. Selective estrogen receptor modulators: a new category of compounds to extend postmenopausal women's health.
Goldstein SR
Int J Fertil Womens Med; 1999; 44(5):221-6. PubMed ID: 10569450
[TBL] [Abstract][Full Text] [Related]
20. Effects of raloxifene in postmenopausal women.
Friedman MN
N Engl J Med; 1998 Apr; 338(18):1313; author reply 1313-4. PubMed ID: 9565493
[No Abstract] [Full Text] [Related]
[Next] [New Search]
